Concepts (110)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Insemination, Artificial | 3 | 2025 | 27 | 1.980 |
Why?
|
| Ovulation Induction | 2 | 2024 | 34 | 1.360 |
Why?
|
| Infertility | 3 | 2024 | 35 | 1.320 |
Why?
|
| Pregnancy Outcome | 3 | 2024 | 131 | 1.130 |
Why?
|
| Progesterone | 3 | 2024 | 129 | 1.070 |
Why?
|
| Pregnancy Rate | 7 | 2025 | 49 | 1.060 |
Why?
|
| Embryo Implantation | 2 | 2015 | 5 | 0.970 |
Why?
|
| Blastocyst | 2 | 2015 | 5 | 0.970 |
Why?
|
| Cryopreservation | 2 | 2015 | 13 | 0.960 |
Why?
|
| Embryo Transfer | 2 | 2015 | 13 | 0.960 |
Why?
|
| Fertility Agents, Female | 2 | 2015 | 15 | 0.960 |
Why?
|
| Sperm Motility | 1 | 2025 | 15 | 0.940 |
Why?
|
| Sperm Count | 1 | 2025 | 17 | 0.940 |
Why?
|
| Spermatozoa | 1 | 2025 | 33 | 0.930 |
Why?
|
| Fertilization in Vitro | 4 | 2021 | 24 | 0.860 |
Why?
|
| Hysterosalpingography | 2 | 2020 | 4 | 0.840 |
Why?
|
| Pregnancy | 8 | 2025 | 1181 | 0.800 |
Why?
|
| Live Birth | 5 | 2024 | 40 | 0.690 |
Why?
|
| Ovarian Reserve | 2 | 2017 | 9 | 0.620 |
Why?
|
| Fallopian Tube Diseases | 1 | 2018 | 2 | 0.620 |
Why?
|
| Oocytes | 1 | 2017 | 24 | 0.560 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2017 | 71 | 0.540 |
Why?
|
| Endometrium | 2 | 2020 | 39 | 0.510 |
Why?
|
| Female | 15 | 2025 | 15156 | 0.510 |
Why?
|
| Oocyte Retrieval | 1 | 2015 | 2 | 0.490 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2015 | 6 | 0.490 |
Why?
|
| Infertility, Female | 1 | 2015 | 43 | 0.470 |
Why?
|
| Prognosis | 1 | 2017 | 803 | 0.460 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 257 | 0.460 |
Why?
|
| Fertility | 1 | 2015 | 58 | 0.460 |
Why?
|
| Adult | 9 | 2025 | 7757 | 0.410 |
Why?
|
| Humans | 16 | 2025 | 28121 | 0.380 |
Why?
|
| Retrospective Studies | 5 | 2025 | 2557 | 0.350 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 2021 | 65 | 0.350 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2011 | 82 | 0.340 |
Why?
|
| Treatment Outcome | 3 | 2017 | 2380 | 0.240 |
Why?
|
| Semen Analysis | 1 | 2025 | 13 | 0.240 |
Why?
|
| Follicular Phase | 1 | 2024 | 8 | 0.230 |
Why?
|
| Birth Rate | 1 | 2024 | 11 | 0.230 |
Why?
|
| Male | 3 | 2025 | 13487 | 0.190 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2021 | 2 | 0.180 |
Why?
|
| Limonins | 1 | 2021 | 3 | 0.180 |
Why?
|
| Semen | 1 | 2021 | 29 | 0.180 |
Why?
|
| Prospective Studies | 1 | 2024 | 1249 | 0.170 |
Why?
|
| Ethiodized Oil | 1 | 2020 | 2 | 0.170 |
Why?
|
| Contrast Media | 1 | 2020 | 97 | 0.160 |
Why?
|
| Water | 1 | 2020 | 135 | 0.160 |
Why?
|
| Insemination | 1 | 2018 | 6 | 0.150 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2018 | 27 | 0.150 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 37 | 0.150 |
Why?
|
| Cystectomy | 1 | 2018 | 104 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 75 | 0.140 |
Why?
|
| Mitochondria | 1 | 2021 | 366 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2021 | 886 | 0.140 |
Why?
|
| Counseling | 1 | 2017 | 53 | 0.140 |
Why?
|
| Lipids | 1 | 2018 | 208 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2018 | 164 | 0.130 |
Why?
|
| Middle Aged | 4 | 2018 | 7164 | 0.130 |
Why?
|
| Cleavage Stage, Ovum | 1 | 2015 | 1 | 0.120 |
Why?
|
| Administration, Intravaginal | 1 | 2015 | 12 | 0.120 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2015 | 1 | 0.120 |
Why?
|
| Treatment Failure | 1 | 2015 | 69 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2015 | 95 | 0.120 |
Why?
|
| ROC Curve | 1 | 2015 | 141 | 0.120 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 223 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 207 | 0.110 |
Why?
|
| Estradiol | 1 | 2015 | 175 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 475 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2018 | 611 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 773 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 2018 | 595 | 0.100 |
Why?
|
| Biomarkers | 1 | 2015 | 755 | 0.090 |
Why?
|
| Receptors, LHRH | 2 | 2021 | 17 | 0.090 |
Why?
|
| Medical History Taking | 1 | 2011 | 18 | 0.090 |
Why?
|
| Papanicolaou Test | 1 | 2011 | 24 | 0.090 |
Why?
|
| Vaginal Smears | 1 | 2011 | 44 | 0.090 |
Why?
|
| Aged | 3 | 2018 | 5416 | 0.080 |
Why?
|
| Young Adult | 2 | 2018 | 2731 | 0.070 |
Why?
|
| Autoantibodies | 2 | 2021 | 474 | 0.070 |
Why?
|
| Adolescent | 1 | 2011 | 3123 | 0.050 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2021 | 18 | 0.050 |
Why?
|
| Biological Assay | 1 | 2021 | 35 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 27 | 0.050 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2021 | 8 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2021 | 33 | 0.040 |
Why?
|
| Testosterone | 1 | 2021 | 70 | 0.040 |
Why?
|
| Epitopes | 1 | 2021 | 179 | 0.040 |
Why?
|
| RNA Interference | 1 | 2021 | 137 | 0.040 |
Why?
|
| Biological Products | 1 | 2021 | 65 | 0.040 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2020 | 17 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 198 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2021 | 345 | 0.040 |
Why?
|
| Peptides | 1 | 2021 | 289 | 0.040 |
Why?
|
| Melanoma | 1 | 2021 | 153 | 0.040 |
Why?
|
| Protein Binding | 1 | 2021 | 656 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2020 | 241 | 0.040 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2018 | 7 | 0.040 |
Why?
|
| Cytokines | 1 | 2021 | 445 | 0.040 |
Why?
|
| Hypolipidemic Agents | 1 | 2018 | 20 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2018 | 53 | 0.040 |
Why?
|
| Carotid Artery Diseases | 1 | 2018 | 37 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2018 | 46 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2021 | 804 | 0.040 |
Why?
|
| Metabolic Syndrome | 1 | 2018 | 78 | 0.040 |
Why?
|
| Mass Screening | 1 | 2018 | 152 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 1324 | 0.030 |
Why?
|
| Cholesterol | 1 | 2018 | 200 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 678 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 2021 | 0.030 |
Why?
|
| Risk Factors | 1 | 2018 | 2084 | 0.030 |
Why?
|